New antibiotic agents for bloodstream infections

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 1, 2008, Pages

  Vergidis, Paschalis I ^a,b   Falagas, Matthew E ^a,c,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b BOSTON MEDICAL CENTER   (United States)

^c HENRY DUNANT HOSPITAL   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic lock therapy; Bloodstream infections; Ceftobiprole; Colistin; Continuous intravenous antibiotic administration; Dalbavancin; Daptomycin; Doripenem; Linezolid; Oritavancin; Quinupristin dalfopristin; Telavancin; Tigecycline

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; COLISTIN; DALBAVANCIN; DALFOPRISTIN; DAPTOMYCIN; DICLOXACILLIN; DORIPENEM; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LEVOFLOXACILIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINUPRISTIN; RIFAMPICIN; SEMISYNTHETIC PENICILLIN; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC LOCK THERAPY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SUBSTITUTION; ENDOCARDITIS; ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION; KIDNEY FAILURE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT FAILURE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 53849103913     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.06.003     Document Type: Article

References (27)

1. Fowler Jr. V.G., Boucher H.W., Corey G.R., Abrutyn E., Karchmer A.W., Rupp M.E., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665
2. Falagas M.E., Giannopoulou K.P., Ntziora F., and Vardakas K.Z. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 60 (2007) 7-19
3. Poutsiaka D.D., Skiffington S., Miller K.B., Hadley S., and Snydman D.R. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 54 (2007) 567-571
4. Segreti J.A., Crank C.W., and Finney M.S. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 26 (2006) 347-352
5. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005) 923-929
6. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., and Schentag J.J. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36 (2003) 159-168
7. Falagas M.E., Siempos I.I., and Vardakas K.Z. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8 (2008) 53-66
8. Drew R.H., Perfect J.R., Srinath L., Kurkimilis E., Dowzicky M., and Talbot G.H. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 46 (2000) 775-784
9. Moellering R.C., Linden P.K., Reinhardt J., Blumberg E.A., Bompart F., and Talbot G.H. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 44 (1999) 251-261
10. Raad I., Darouiche R., Vazquez J., Lentnek A., Hachem R., Hanna H., et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 40 (2005) 374-380
11. Chambers H.F. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 884-888
12. Mushtaq S., Ge Y., and Livermore D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother 48 (2004) 1313-1319
13. Fritsche T.R., Stilwell M.G., and Jones R.N. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 11 (2005) 974-984
14. Chastre J., Wunderink R., Prokocimer P., Lee M., Kaniga K., and Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36 (2008) 1089-1096
15. Jones R.N., Huynh H.K., and Biedenbach D.J. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 48 (2004) 3136-3140
16. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., and Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 60 (2007) 1018-1029
17. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59 (2007) 128-131
18. Maroko R., Cooper A., Dukart G., Dartois N., and Gandjini H. Results of Phase 3 study comparing a tigecycline (TGC) regimen with an imipenem/cilastatin (IMI) regimen in treatment of patients (Pts) with hospital-acquired pneumonia (HAP). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 17-20 September; Chicago, IL (2007)
19. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., and Falagas M.E. Tigecycline for the treatment for multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62 (2008) 45-55
20. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40 (2005) 1333-1341
21. Falagas M.E., and Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10 (2006) R27
22. Kasiakou S.K., Michalopoulos A., Soteriades E.S., Samonis G., Sermaides G.J., and Falagas M.E. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 49 (2005) 3136-3146
23. Falagas M.E., and Rafailidis P.I. When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach. Shock 27 (2007) 605-609
24. Reynolds R., Hope R., and on behalf of BSAC Working Party on Bacteraemia Resistance Surveillance. Resistance in Pseudomonas aeruginosa and Acinetobacter spp. from blood in the UK and Ireland, 2001-2005. 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 31 March-3 April; Munich, Germany (2007)
25. Korbila I.P., Bliziotis I.A., Lawrence K.R., and Falagas M.E. Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current evidence. Expert Rev Anti Infect Ther 5 (2007) 639-652
26. Kasiakou S.K., Lawrence K.R., Choulis N., and Falagas M.E. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 65 (2005) 2499-2511
27. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., and Falagas M.E. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5 (2005) 581-589